共查询到20条相似文献，搜索用时 187 毫秒
1.
郭全辉 《青海畜牧兽医杂志》2009,39(3):M0002-M0002
犬细小病毒性肠炎是由犬细小病毒引起犬的一种急性传染病，临床治疗常以对症疗法和支持疗法为主，但实践证明，疗效不明显。笔者采用中西医结合治疗犬细小病毒性肠炎共计22例、治愈19例，好转2例，无效1例，治愈率达86％．取得了满意疗效。 相似文献
2.
犬细小病毒性肠炎是由细小病毒引起的以呕吐、腹泻、便血为特征的急性传染病。本病常见于3岁以下犬，尤其是断乳后3～6月龄幼犬最易感染，发病率、病死率均很高，对犬的危害极大。笔者自1991年接诊犬细小病毒性肠炎232例，采用中西医结合治愈203例，治愈率达87．5％。现将中西医结合治疗犬细小病毒性肠炎的临床经验报道如下。 相似文献
3.
4.
5.
犬细小病毒病又称犬病毒性肠炎,是犬细小病毒（CPV）引起的犬的一种急性传染病,临床上多以出血性肠炎或非化脓性心肌炎为主要特征,死亡率高,治愈率低。笔者对本病的诊断和治疗方法进行了总结和探讨,现报道如下,供参考。 相似文献
6.
犬细小病毒性肠炎又叫犬传染性肠炎，是犬的一种具有高度接触性的传染性疾病，临床上以急性出血性肠炎和非化脓性心肌炎为主要特征。2007年以来，笔者共收治病犬85例，采用云南白药内服，配合补液，抗病毒等综合治疗措施，除13例因治疗不及时死亡外共治愈72例，治愈率为84．7％。现将诊治情况报告如下。 相似文献
7.
犬细小病毒性肠炎又称犬传染性肠炎，是由犬细小病毒引起的犬的一种高度接触性、急性、致死性消化道障碍性传染病，临床上以剧烈呕吐、腹泻和脱水为主要特征。笔者于1989—2000年先后收治这种病犬54例，治愈率68．5％(37／54），现报道如下。 相似文献
8.
用犬细小病毒高免血清以肢内侧肌肉注射、腹腔注射、静脉滴注三种不同注射途径对87例患犬细小病毒性肠炎病大进行治疗，结果治愈率为68．2％、75.9％、91.7％。大多数病犬康复时间分别为4天、3天、2天。其中静脉滴注治愈率明显高于肌肉注射（P＜0．05），且康复时间也最短。 相似文献
9.
用３％腐敏散水溶液灌肠并配合常规疗法，对７０条患细小病毒性肠炎的犬进行治疗，总有效率为９５．７１％；对患非细小病毒性胃肠炎的１１０条病犬，采用３％腐敏散溶液大剂量短时间保留灌肠疗法，轻症病例一次即愈，重症病例配合强心、补液疗法，３～５次痊愈，治愈率为１００％。 相似文献
10.
用３％腐敏散水溶液灌肠并配合常规疗法，对７０条患细小病毒性肠炎的犬进行治疗，总有效率为９５．７１％；对患非细小病毒性胃肠炎的１１０条病犬，采用３％腐敏散溶液大剂量短时间保留灌肠疗法，轻症病例一次即愈，重症病例配合强心、补液疗法，３￣５次痊愈，治愈率为１００％。 相似文献
11.
旨在观察犬细小病毒特异性免疫球蛋白治疗犬细小病毒病的临床应用效果,本文收集了中国农业大学动物医院自2016年1月—2019年11月接治的犬细小病毒病患犬的病历资料,筛选出病历资料完整的并使用了犬细小病毒单抗或犬细小病毒特异性免疫球蛋白治疗的患犬病例进行跟踪以及回访。对收集的病例数据进行了总治愈率、各初始抗体水平的治愈率、各月龄段的治愈率和治愈病例的病程分析。结果显示,犬细小病毒特异性免疫球蛋白和犬细小病毒单克隆抗体在总治愈率、相同初始抗体水平治愈率、相同月龄段治愈率均无显著差异（P>0.05）。但使用特异性免疫球蛋白的病例痊愈时间显著低于使用单克隆抗体的病例（P=0.02<0.05）。综上表明,犬细小病毒特异性免疫球蛋白的临床应用效果良好,可为犬细小病毒病的治疗提供新的药物选择。 相似文献
12.
采用犬细小病毒单克隆抗体（CPVMcAb）配合静脉注射用犬免疫球蛋白及静脉注射用犬血白蛋白,采用股内侧肌肉注射对172例细小病毒病患犬进行临床治疗试验。共治愈140例,治愈率为81．40％。采取以上治疗方案,结合对症支持治疗,发病1d的患犬治愈率90．70％,发病2d的患犬治愈率为85．29％,发病3d的患犬治愈率为56．25％,发病4d的患犬治愈卒为72．73％,发病5、d的患犬治愈率为77．78％。94．29％的治愈犬（132只）用药后4d内完全康复。采用该治疗方案,进入犬体内的McAb能迅速到达全身各组织,中和淋巴组织及血循环中的病毒,阻止病原复制和扩散;同时,中和反应形成抗原抗体复合物,可促进机体的主动免疫反应,促进患犬逐渐康复。该研究结果对提高犬细小病毒病的临床治疗效果具有积极的应用价值。 相似文献
13.
Canine parvovirus (CPV) and canine distemper virus (CDV) infections are relatively common in animal shelters and are important population management issues since the immune status of incoming dogs is usually unknown. This study aimed to determine the prevalence of positive antibody test results for CPV and CDV in incoming dogs aged ≥ 4 months and to measure antibody response over 2 weeks following vaccination with a modified live vaccine (MLV). Dogs aged 4-24 months entering an adoption-guarantee shelter (Shelter 1, n=51) and aged ≥ 4 months entering a limited admission shelter (Shelter 2; n=51) were enrolled. Dogs from Shelter 1 had been vaccinated with MLV at a municipal shelter 5 days before enrollment, whereas dogs from Shelter 2 had no known history of vaccination at enrollment. Sera were obtained on day 1, immediately prior to CPV/CDV MLV, and tested using an in-clinic ELISA kit to detect CPV/CDV antibodies. Dogs negative for CPV and/or CDV were retested at day 6-8 and those dogs still negative at day 6-8 were retested at day 13-15. Prior to CPV/CDV MLV on day 1, more dogs tested positive for CPV (Shelter 1 - 68.6%; Shelter 2 - 84.3%) than for CDV (Shelter 1 - 37.3%; Shelter 2 - 41.2%). On day 1, prior to MLV, all spayed/neutered animals tested CPV antibody-positive (n=17/102) and CPV antibody-positive dogs were older than serologically negative dogs (Shelter 1, P=0.0029; Shelter 2, P=0.0042). By day 13-15, almost all dogs were CPV antibody-positive (Shelter 1 - 97.9%; Shelter 2 - 100.0%) and CDV antibody-positive (Shelter 1 - 93.8%; Shelter 2 - 97.8%). MLV induces protective antibody titers against CPV/CDV in almost all dogs after 13-15 days. 相似文献
14.
Repeated suppression of lymphocyte blastogenesis following vaccinations of CPV-immune dogs with modified-live CPV vaccines 总被引：1，自引：0，他引：1
J M Mastro M Axthelm L E Mathes S Krakowka W Ladiges R G Olsen 《Veterinary microbiology》1986,12(3):201-211
A commercially available modified-live canine parvovirus (CPV) vaccine was evaluated for its immunosuppressive properties in eight random-bred dogs, all with circulatory antibody to CPV. Three of the eight dogs exhibited a significant decrease in lymphocyte blastogenesis after vaccine administration. In these dogs, this decrease in blastogenesis was of short duration and was consistently observed after repeated administrations of the vaccine. Neither gastroenteritis, fever nor leukopenia, signs indicative of virulent canine parvovirus infection, were detected in these animals. In addition, lymphocytes from these dogs lacked Ia antigen expression. This study demonstrated that the immunomodulating effects of ML-CPV is not observed in all animals yet is consistent in affected individuals. 相似文献
15.
The ability of dogs vaccinated with a live attenuated CPV type 2 (Nobivac Intervet) vaccine to resist challenge with a current CPV2c isolate was investigated. Six SPF beagle dogs were given the minimum recommended course of vaccination, comprising a single inoculation of vaccine (Nobivac Lepto+Nobivac Pi) at 8-10 weeks of age followed 3 weeks later with a parvovirus vaccine in combination with distemper, adenovirus and parainfluenza virus (Nobivac DHPPi) and a repeat leptospirosis vaccine. Six control dogs were kept unvaccinated. All animals were challenged orally with a type 2c isolate of CPV and monitored for clinical signs, virus shedding, white blood cell fluctuations and serological responses. All vaccinated dogs were fully protected; showing no clinical signs nor shedding challenge virus in the faeces, in contrast to control animals, which displayed all the typical signs of infection with pathogenic CPV and shed challenge virus in the faeces. 相似文献
16.
Comparison of the blastogenic response of peripheral blood lymphocytes from canine parvovirus-positive and -negative outbred dogs 总被引：1，自引：0，他引：1
Lymphocyte blast transformation assays (LBT) were performed on canine parvovirus (CPV) -positive and -negative mongrel dogs randomly selected from a humane facility. Concanavalin A as well as Phytohemagglutinin P stimulation was depressed (p less than 0.001) in the group of animals shedding CPV compared to CPV-negative dogs. 相似文献
17.
Between 18 July 1980 and 2 January 1981, 188 samples (145 faeces and 43 intestinal contents) were submitted from dogs with suspected canine parvovirus (CPV) enteritis. CPV was demonstrated in 56 (30%) of these samples; the weekly rate of positive CPV identification was remarkably constant at approximately 30% even though clinical and often post-mortem findings strongly supported a diagnosis of CPV enteritis. The simplest, most sensitive and most rapid method for detection of virus was haemagglutination (HA) which was twice as sensitive as isolation of virus and 8 times as sensitive as electron microscopy (EM). Forty nine of 56 (88%) samples positive for CPV were from dogs less than 1 year old and 44 (79%) CPV-positive samples were from pups less than 6 months old; only one sample from a pup less than 2 months old (pup was 7 weeks old) was positive. An additional 68 samples (53 faeces and 15 intestinal contents) were submitted from Beagle dogs that were part of a colony of approximately 1200 dogs. Epidemiological data pinpoints the entry of CPV into the colony in November 1978 at which time most dogs including pups less than 6 months of age developed antibody to CPV without developing clinical disease. From these data an overview of some aspects of the pathogenesis and epidemiology of CPV is constructed. 相似文献
18.
Breed-related risk factors for canine parvovirus enteritis 总被引：2，自引：0，他引：2
L T Glickman L M Domanski G J Patronek F Visintainer 《Journal of the American Veterinary Medical Association》1985,187(6):589-594
Case records of 305 dogs with canine parvovirus (CPV) enteritis, seen at the Veterinary Hospital of the University of Pennsylvania from July 1, 1981 to Aug 31, 1982, were selected on the basis of admitting diagnoses or signs of diarrhea and vomiting. The case records were subdivided into 3 diagnostic categories, based on final diagnoses and laboratory test results. There were 96 dogs with definite CPV enteritis, 139 with possible CPV enteritis, and 70 with unlikely CPV enteritis. These cases were then stratified by animal's age (less than or equal to 6 months or greater than 6 months) and specific hospital service (medicine or emergency). A control group was selected from all canine case records from the Veterinary Hospital of the University of Pennsylvania for conditions other than the criteria used in selecting the case group. Approximately 2 hospital patients were selected for each CPV enteritis case by frequency matching for hospital service and age. The proportion of dogs with definite CPV enteritis that had each of the clinical signs that were studied was greater than that of dogs in the other CPV enteritis diagnostic categories. The overall survival rate for dogs with definite CPV enteritis was 64.0%; survival was not associated with any given clinical sign of disease. Odds ratios (OR) for the risk of CPV enteritis were calculated for breeds with 3 or more dogs with definite CPV enteritis. The Doberman Pinschers (OR = 3.1), Rottweilers (OR = 6.0), and English Springer Spaniels (OR = 8.1) had a significantly increased risk of CPV enteritis.(ABSTRACT TRUNCATED AT 250 WORDS) 相似文献
19.
S E Stann R F DiGiacomo W E Giddens J F Evermann 《Journal of the American Veterinary Medical Association》1984,185(6):651-655
From June 1980 through May 1982, 161 pound-source dogs that developed diarrhea while being used in research were evaluated to determine whether canine parvovirus (CPV) type 2 was the etiologic agent. Evaluation included notation of clinical signs, determination of serum CPV-specific immunoglobulin (Ig) M and IgG titers, virus isolation attempts, and histologic examination of tissues. Criteria for diagnosis of canine parvoviral enteritis were serum CPV-specific IgM antibodies, isolation of CPV from feces, and histologic evidence of intestinal crypt cell necrosis. Upon arrival, 67 clinically normal pound-source dogs were evaluated to determine the prevalence of fecal shedding of CPV and to determine their antibody titers to CPV. Parvovirus was not isolated from any of these dogs, although 76% had IgG antibodies and 3% had IgM antibodies. Of the 161 dogs with diarrhea, 40 (25%) had parvoviral enteritis. Of dogs with parvoviral enteritis, 71% had IgG antibodies and 68% had IgM antibodies. Canine parvovirus was isolated from 18 dogs. Serum IgG antibodies were found in 85% of dogs with diarrhea due to other causes. The geometric mean titer of IgG antibodies to CPV was not significantly different among the 3 groups. Clinical signs that appeared significantly (P less than 0.05) more often in dogs with parvoviral enteritis included bloody diarrhea, anorexia, fever (greater than or equal to 39.4 C), and leukopenia (WBC less than 6,000/mm3). Cases occurred throughout the year, without apparent seasonal variation. The duration between arrival and onset of diarrhea was significantly (P less than 0.05) shorter for dogs with parvoviral enteritis.(ABSTRACT TRUNCATED AT 250 WORDS) 相似文献
20.
OBJECTIVE: To assess whether serum canine parvovirus (CPV) and canine distemper virus (CDV) antibody titers can be used to determine revaccination protocols in healthy dogs. DESIGN: Case series. ANIMALS: 1,441 dogs between 6 weeks and 17 years old. PROCEDURE: CPV and CDV antibody titers in serum samples submitted to a commercial diagnostic laboratory were measured by use of indirect fluorescent antibody (IFA) tests. On the basis of parallel measurements of CPV and CDV serum antibody titers in 61 paired serum samples determined by use of hemagglutination inhibition and serum neutralization methods, respectively, we considered titers > or = 1:5 (IFA test) indicative of an adequate antibody response. RESULTS: Age, breed, and sex were not significantly associated with adequate CPV- or CDV-specific antibody responses. Of 1,441 dogs, 1,370 (95.1%) had adequate and 71 (4.9%) had inadequate antibody responses to CPV, whereas 1,346 of 1,379 (97.6%) dogs had adequate and 33 (2.4%) had inadequate responses to CDV. Vaccination histories were available for 468 dogs (468 for CPV, 457 for CDV). Interval between last vaccination and antibody measurement was 1 to 2 years for the majority (281/468; 60.0%) of dogs and 2 to 7 years for 142 of 468 (30.3%) dogs. Interval was < 1 year in only 45 of 468 (9.6%) dogs. CONCLUSIONS AND CLINICAL RELEVANCE: The high prevalence of adequate antibody responses (CPV, 95.1%; CDV, 97.6%) in this large population of dogs suggests that annual revaccination against CPV and CDV may not be necessary. 相似文献